Mental Health

Official Title

Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD (TERPSIS)

Purpose

To evaluate the efficacy and safety of study drug NBI-1065846, used as adjunctive treatment to oral antidepressant medication(s), compared with a placebo when treating symptoms of anhedonia.

Could this study be right for you?

• Aged 18-65 years old • Diagnosis of MDD • Currently on stable dose of at least one antidepressant • Experiencing anhedonia (low interest, decreased enjoyment)

Age Range

18 and up

Official Title

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

Purpose

The purpose of this study is to examine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.

The duration of the study will consist over a 5 year period. You will visit the study site approximately 23 times after your implant surgery.

Could this study be right for you?

• Aged 18 years or older
• Must be in a major depressive episode (MDD or bipolar disorder) for ≥ two years or have at least had four episodes of depression including the current episode
• Patients depressive illness meets a minimum criteria of four prior failed treatments of adequate dose and duration

Age Range

18 and up

Official Title

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants with Treatment-resistant Depression

Purpose

The purpose of this study is to see if esketamine nasal spray alone is effective as a medication to improve depressive symptoms in adults with treatment-resistant depression when compared with placebo nasal spray.

The duration of the study consists up to a maximum of 24 weeks.

Could this study be right for you?

• Aged 18 years or older
• Must have had no response (less than 25% improvement) to at least 2 oral antidepressant treatments in the current episode of depression

Age Range

18 and up

Official Title

Neural Mechanisms and Predictors of an Ultra-Brief Suicide Prevention Strategy

Purpose

This research study will look at how patterns of brain activity influence thoughts and behaviors. This research is being done to better explain why people have thoughts about suicide and how different suicide prevention strategies impact brain responses to emotional information.

Could this study be right for you?

Eligibility Criteria includes:
- 18-65 years old
- generally medically and physically healthy
- current suicidal ideation and intent OR no lifetime history of DSM-5 disorder, no lifetime suicidal intent or lifetime suicide attempts
(partial list of inclusion criteria)

Exclusion Criteria:
- Diagnosis of bipolar disorder, schizophrenia, mania, or psychosis
- Currently pregnant (positive pregnancy test), or trying to become pregnant (female)
- Presence of ferrous-containing metal in the body
- Inability to tolerate enclosed spaces
(partial list of exclusion criteria)

Age Range

18 and up

Official Title

Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) and COVID Pandemic-related Stress

Purpose

The purpose of this study is to better understand how Mindfulness-based Mind-Body therapies work to help people with Posttraumatic Stress and Stress and Anxiety related to the COVID Pandemic. We want to learn more about how these treatments work so we can put together better treatments for people with PTSD and stress or worry. Time in the study altogether is generally about 16-18 weeks

Could this study be right for you?

For those suffering from PTSD: - Must be between 18 – 72 years of age - Must have current clinically significant symptoms of PTSD - Must be able to come to OSU Columbus campus for fMRI brain scan - Must be appropriate for group therapy Eligibility for those with Pandemic Stress: - Must be between 18 – 72 years of age - Must have current stress related to the pandemic - Must reside in selected zip codes / under-resourced areas in central Ohio (areas with high levels of residents with incomes near the poverty line) - Must be able to come to OSU Columbus campus for fMRI brain scan - Must be appropriate for group therapy - May have up to moderate depression and/or anxiety

Age Range

18 and up

Official Title

Mechanisms of Self and Other Evaluation (MeSO Study)

Purpose

The purpose of this study is to better understand the way the brain works in people who have depression and people who have previously been depressed. We are also testing healthy subjects for comparison. We hope our findings will lead to better ways to diagnose and treat mood disorders in the future. Participation involves an initial phone call and a 2 to 4 hour visit to find out if you are eligible. This visit will include completing questionnaires and interviews. If eligible, participants will have a second 3-5 hour visit for an MRI scan. Two months after the scan, participants will complete daily online questionnaires for 7 days. This process is repeated 2 months later (4 months after the scan). 

Could this study be right for you?

You may be eligible for this study if you: • Are between the ages of 18-40 • Are right-handed • Do not have a history of neurological disorders (e.g., seizures, head injury, etc.) • Do not have major medical problems (e.g., stroke, heart disease, high blood pressure, endocrine disorders, etc.) • Have normal vision, vision that is corrected to normal with glasses or contacts • Are willing and able to undergo fMRI scanning (not claustrophobic, no non-removable metal in your body) • Are not pregnant

Age Range

18 and up

Official Title

Mechanisms of Negative Affectivity

Purpose

Symptoms related to depression and anxiety can affect a person’s daily life and relationships. Some research suggests that people with mood and anxiety disorders process information differently than people without these types of disorders.

The purpose of this study is to better understand the way the brain works in people who have depression and anxiety. Researchers hope their findings will lead to better ways to diagnose and treat mood and anxiety disorders in the future.

Participation involves an initial phone call and a 3 to 5 hour visit to find out if you are eligible. This visit will include completing questionnaires and interviews. If eligible, participants will have a second 3-5 hour visit for an MRI scan.

The 3rd and 4th visits (at 6 and 12 months) will include 1.5 to 3 hours of questionnaires and interviews each.

Following the scan, the 6-month follow-up, and the 12-month follow-up, participants will also complete daily online questionnaires for 7 days.

Could this study be right for you?

You may be eligible for this study if you are:
• 18-25 years of age
• Right-handed
• Currently experiencing symptoms of depression or anxiety (feeling down or depressed, anxious, nervous, or tense, having no interest in things you used to enjoy, or feeling hopeless)
• Not currently receiving treatment (psychiatric medications or therapy)
• No major medical problems (e.g., stroke, heart disease, high blood pressure, endocrine disorders, etc.)
• No history of neurological disorders (e.g., seizures, head injury, etc.)
• Normal vision, vision that is corrected to normal with glasses or contacts
• Willing and able to undergo fMRI scanning (not claustrophobic, no non-removable metal in your body)
• Not pregnant

Participation involves an initial phone call and a 3 to 5 hour visit to find out if you are eligible. This visit will include completing questionnaires and interviews. If eligible, participants will have a second 3-5 hour visit for an MRI scan.

The 3rd and 4th visits (at 6 and 12 months) will include 1.5 to 3 hours of questionnaires and interviews each.

Following the scan, the 6-month follow-up, and the 12-month follow-up, participants will also complete daily online questionnaires for 7 days.

Age Range

18 and up

Official Title

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in people with Depression

Purpose

The purpose of this study is to see if a new drug (BI 1358894), taken in addition to a current antidepressant, is useful and safe for treating patients with Major Depressive Disorder.

You will be in this study approximately 13 weeks and have about 8 visits to the study center. You will also have about 2 visits that will be done by phone.

Could this study be right for you?

Inclusion criteria:
- Between the ages of 18 and 65
- Currently taking an antidepressant
- Currently experiencing symptoms of depression

Age Range

18 and up

Official Title

Parental History of Suicidal Behavior and Early Markers of Risk in Pre-pubescent Youth

Purpose

The purpose of this study is to learn what factors may be related to suicide attempt(s) in children (ages 6 - 9) that have a parental history of suicidal behavior in hopes that this information will help prevent and treat self-harm behavior in youth at high risk.

Both parents and children will complete questionnaires, interview questions, and a family discussion in addition to problem solving tasks and computer games.

There are multiple study visits. The first will last about 2.5 to 3 hours and all other appointments will occur annually from your first appointment. Due to COVID-19, families will have the option to conduct annual follow-up appointments via telephone. These annual telephone visits will last approximately 30-45 minutes. If the annual visit is conducted in-person, it will last 1.5 to 2.5 hours.

Could this study be right for you?

- Parents and children must be able to read and understand English fluently
- Child is 6 to 9 years of age
- Meet other criteria (e.g., no traumatic brain injury) for the study

Age Range

6 and up

Official Title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults with Major Depressive Disorder

Purpose

Brexpiprazole is a medication being studied as a possible treatment for adjunctive treatment for Major Depressive Disorder (MDD). The reason for this study is to find out about the potential benefits and safety of Brexpiprazole.

Could this study be right for you?

Inclusion criteria: - Between the ages of 18 and 65 - Currently depressed - Currently taking an antidepressant - Have tried at least 2 antidepressant medications

Age Range

18 and up